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Global Hib vaccination: reasons to cheer and fear
Conjugate Haemophilus inﬂ uenzae type b (Hib) 
vaccination is one of the major global health 
achievements of the past three or four decades. 
H inﬂ uenzae type b is a key cause of disease and death 
in unvaccinated populations, and that burden falls 
most severely on young children. Those of us at medical 
schools in developed countries in the late 1980s learned 
about H inﬂ uenzae type b disease but rarely saw it in 
practice, such was the eﬀ ectiveness of the conjugate 
vaccine introduced in those settings in the 1990s. At 
that time the disease’s principal impact was to be seen in 
low-income countries, which would not use the vaccine 
for years.
More than 90% of countries now routinely provide 
conjugate Hib vaccine to their children, a proportion 
that was achieved through an impressive global public 
health push. However, the world is divided on the dosing 
schedule used: the vast majority of developed countries 
give a booster dose at age 12–23 months, whereas most 
low-income countries do not. WHO policy is a three-
dose primary series in infancy with no booster, and 
vaccine funding for low-income countries follows this 
recommendation. For health agencies and experts in 
the ﬁ eld, the question of whether low-income countries 
should have a booster dose is one that is not going away. 
Therefore, the report in The Lancet Global Health by 
Laura Hammitt and colleagues,1 who have assessed 
Hib vaccine eﬀ ectiveness, nasopharyngeal carriage, 
and population immunity in Kenya, is important. The 
investigators report that the introduction in 2001 of 
routine conjugate Hib vaccination with a three-dose 
primary series without a booster resulted in a major 
and sustained reduction in invasive Hib disease in the 
Kiliﬁ  district of Kenya over 13 years. This adds to earlier 
evidence of sustained long-term control of disease with 
the same schedule in The Gambia, the ﬁ rst country in 
Africa to introduce the vaccine in 1997.2
So why should we worry that the vaccine will stop 
working, or stop working so well, without a booster? 
There are both empirical and theoretical reasons to 
worry. Good long-term control has not occurred in all 
countries that have started with a three-dose primary 
series alone. The UK introduced Hib vaccine in 1993 and 
was one of the few developed countries not to schedule 
a booster dose from the outset. Control was excellent 
initially3 and H inﬂ uenzae type b carriage in the upper 
respiratory tract was eliminated,4 but after several years 
a resurgence of disease prompted the introduction 
of a booster dose in 2003, which was associated with 
a return to good control.3 This resurgence in disease 
was concerning, and Ireland seemed to have a similar 
experience to the UK.5 
Another, theoretical, reason to worry is that immunity 
of vaccinated children to H inﬂ uenzae type b infection 
could wane over the years (by contrast with earlier 
generations whose immunity was based on exposure to 
the pathogen itself). In this state of lowered immunity, 
this vaccinated group might form a new reservoir of Hib 
carriage and disease (typically mild disease) and expose 
young children to greater risk of disease, typically severe. 
This kind of dynamic contributes to resurgences in 
another disease, pertussis. Clearly, a booster dose might 
help to avert this. Mexico introduced a booster in 2007 
in the face of evidence of waning immunity in children.6
The evidence from Kenya for sustained immunity 
in older children and the absence of a H inﬂ uenzae 
type b reservoir in that group partly allays concerns 
about waning immunity with long-term use of Hib 
vaccine, but not completely. Diﬀ erent contexts have 
varying factors at play, and the Hib vaccine has not been 
in use in enough low-income countries for long enough 
to be sure that no pitfalls await. Indeed, Mackenzie 
and colleagues7 reported a resurgence of disease in The 
Gambia beyond 14 years of vaccine use. 
So what can be done? It is tempting to recommend 
a uniﬁ ed global policy of a booster dose and be done 
with it. This solution will not suﬃ  ce though because of 
constrained budgets, competing priorities, complicated 
logistics, and, crucially, a lack of evidence for its 
necessity. But doing nothing is not an option. Countries 
must ﬁ rst be vigilant with disease surveillance—they 
will not know if they have a problem unless disease 
burden is measured, a principle that clearly applies 
not just to H inﬂ uenzae type b disease. Second, the 
dynamics of H inﬂ uenzae type b control and resurgence 
must be better understood in varying contexts to avoid 
countries being caught unprepared by resurgent disease. 
The world has enough challenges without letting this 
disease get a second hold on countries that have already 
taken actions against it. 
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